Are peptide injections safe? What is known and unknown

The short answer: peptide injections are as safe as the product in the syringe, and the product matters more than the word "peptide." FDA-approved peptide drugs such as semaglutide, tirzepatide, and tesamorelin have documented side effects, drawn from clinical trials and printed on their labels. [1] Compounded versions are not FDA approved, so no one at FDA reviewed their safety, effectiveness, or quality before they were sold. [4] Research-only peptides sold online add a further layer of unknowns: whether the vial holds the right substance, in the right amount, free of contamination. [9]

This page separates what is documented from what is unknown. It is not medical advice, and it does not give dosing instructions.

Three kinds of peptide injections, three safety records

"Peptide injection" covers three different things, and what peptide therapy is explains each in detail:

1. FDA-approved peptide drugs. Made by a manufacturer under FDA's manufacturing rules, tested in randomized trials, and sold with a label that lists known risks. Examples include the GLP-1 drugs for weight and diabetes and tesamorelin for HIV-associated abdominal fat. [3]
2. Compounded peptides. Mixed by a pharmacy for an individual prescription. Compounded drugs are not FDA approved, and FDA does not verify their safety, effectiveness, or quality before they reach patients. [4]
3. Research-only peptides. Sold online labeled "for research purposes" or "not for human consumption," often with dosing instructions anyway. FDA says these products are of unknown quality and may be harmful. [5]

The safety question has a different answer for each group.

Side effects of FDA-approved peptide injections

For approved drugs, the side effects are known well enough to be counted.

GLP-1 injections. On the semaglutide label for weight management, the most common adverse reactions (5% or more) include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, and hair loss. [1] The label also warns about acute pancreatitis, acute gallbladder disease, low blood sugar when combined with insulin or insulin secretagogues, acute kidney injury from dehydration, severe gastrointestinal reactions, allergic reactions, and a rise in heart rate. [1] Both the semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors seen in rodents; whether the drugs cause these tumors in humans is unknown. [1] [2] Our GLP-1 side effects ranking orders these by how often they occur.

Tesamorelin. The most commonly reported adverse reactions (more than 5%) on the tesamorelin label are joint pain, injection site redness, injection site itching, pain in the arms or legs, swelling in the legs or feet, and muscle pain. [3]

The same logic applies to the non-peptide drugs often compared with peptides: their labels spell out known risks, as in sildenafil vs Viagra and oral minoxidil for hair loss. The point is not that approved drugs are harmless. It is that their risks were measured in trials, written down, and are monitored after approval, so a prescriber can weigh them against the benefit for a specific person.

Are compounded peptide injections safe?

Compounding is legal for some peptides and can be appropriate when an approved drug does not meet a patient's needs, but the safety evidence for any given compounded vial is thinner. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. [5] Four documented problems show where the risk sits.

Sterility. An injectable has to be sterile, and compounding failures have killed people. In 2012, contaminated methylprednisolone injections from a single compounding pharmacy caused 749 reported fungal infections in 20 states, with 61 deaths, by July 2013. [6] That drug was a steroid, not a peptide, but the failure mode, a contaminated injectable from one pharmacy, applies to any compounded injection.

Dosing errors. Compounded GLP-1 drugs usually come in multi-dose vials drawn up with a syringe, not in prefilled pens. A poison control center reported three patients with adverse events after using compounded semaglutide, two of whom injected ten times the intended dose; one measured in milliliters and units rather than milligrams. [7] FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded semaglutide, including errors by health care professionals calculating doses. [5]

Handling. FDA recommends discarding a multi-dose vial 28 days after first use, because the contamination risk rises after that, and says not to use an injectable GLP-1 that arrives warm. [5]

Reported adverse events. As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Federal law does not require most state-licensed pharmacies to report adverse events, so FDA says these are likely underreported. [5]

If you are prescribed a compounded peptide, how to get peptides prescribed covers which ones have a lawful path and the red flags that mean a product is not a real prescription. The regulatory tracker follows the status of each one.

Research peptides: the four unknowns

Products sold as research chemicals have no prescription, no pharmacist, and no regulator checking the vial. Studies that bought and tested them show why each of four basic questions is open.

Identity: is it the right substance? A 31-year-old woman was admitted in a hypoglycemic coma after injecting a product sold online as semaglutide. Toxicology found insulin in the vial instead. [10]

Dose accuracy: how much is in the vial? Researchers who bought semaglutide from illegal online sellers found the semaglutide content exceeded the labeled amount by 28.56% to 38.69%. [9]

Purity: what else is in it? The same vials had a measured semaglutide purity of 7.7% to 14.37%, against the 99% claimed on the labels. [9]

Contamination: is it sterile? The freeze-dried samples had no living microorganisms at the time of testing, but bacterial endotoxin was found in every sample. [9] Three prefilled pens ordered in the same study never arrived at all. [9]

For peptides that were never approved, the uncertainty starts before manufacturing. On its list of bulk substances that may present significant safety risks, FDA wrote that compounded BPC-157 may pose a risk of immunogenicity (an immune reaction against the peptide) for certain routes, may have complexities with peptide-related impurities, and has no or only limited safety information, so FDA "lacks sufficient information" to know whether it would cause harm in people. [8] Follow its status on the BPC-157 regulatory page. Investigational drugs such as retatrutide cannot be used in compounding at all, and FDA has warned companies selling it and other GLP-1 drugs labeled "for research purposes." [5]

A 2026 clinical review listed the potential risks of unregulated injectables as product contamination, manufacturing impurities, inaccurate dosing, and, depending on the compound, cardiovascular and hormonal harms. [12]

Self-injection is its own risk. When 20 adults were handed semaglutide vials, diluent, and supplies and asked to prepare an injection using only information found online, they completed 15 of 34 steps correctly on average, with errors that could cause wrong doses, needle-stick injuries, or infections. [11]

What FDA adverse event reports can and cannot tell you

FDA's adverse event database, formerly called FAERS and now part of the Adverse Event Monitoring System, collects reports of adverse events, medication errors, and product quality complaints to support safety monitoring after a drug is on the market. [13] Two limits matter when you read numbers from it:

• A report is not proof of cause. FDA notes that it is not always possible to determine whether an adverse event resulted from the drug or from other factors. [5]
• Missing reports are not proof of safety. Most compounding pharmacies do not have to report, and research-chemical sellers report nothing. [5] A peptide with few reports may simply be one that nobody is tracking.

You can report a side effect or a suspect product yourself through MedWatch. [14]

How to lower the risk

These steps come from FDA guidance, not from us:

• Use an FDA-approved product when one fits your need; compounded drugs are meant for patients whose needs an approved drug cannot meet. [5]
• Get a prescription from a licensed prescriber and fill it at a state-licensed pharmacy; FDA's BeSafeRx campaign explains how to check an online pharmacy. [15]
• Do not buy products labeled "for research purposes" or "not for human consumption" for your own use. [5]
• Report problems through MedWatch. [14]

State rules on compounding and telehealth prescribing vary; see our state law pages. For weight-loss peptides specifically, the obesity page grades every option by evidence.

The takeaway

Are peptides safe? The approved ones have known, measured risks that a prescriber can manage. Compounded peptides are legal in some cases but skip FDA's premarket review, and their documented problems are contamination, dosing errors, and underreported side effects. Research-only peptides are the least known of all: tests of products sold online found the wrong amount, low purity, endotoxin, and in one case the wrong drug entirely.